Status:
COMPLETED
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus Type 2
Eligibility:
All Genders
30-75 years
Phase:
PHASE2
Brief Summary
This study will evaluate the long-term safety and tolerability of GK Activator (2) at doses ranging from 25mg - 100mg po bid, administered alone or in combination with metformin, in patients with type...
Eligibility Criteria
Inclusion
- type 2 diabetic patients who have completed studies BM18248 or BM18249;
- patients considered by the investigator to be suitable for long term treatment with GK Activator (2).
Exclusion
- type 1 diabetes mellitus;
- women who are pregnant, breast-feeding or not using adequate contraceptive methods.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT00316758
Start Date
February 1 2006
End Date
October 1 2007
Last Update
November 2 2016
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Chula Vista, California, United States, 91910
2
Chula Vista, California, United States, 91911
3
Los Angeles, California, United States, 90057
4
Spring Valley, California, United States, 91978